- Home
- NTIC vs CYCC Comparison
NTIC vs CYCC Comparison
Compare NTIC & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIC
- CYCC
- Stock Information
- Founded
- NTIC 1970
- CYCC 1992
- Country
- NTIC United States
- CYCC Malaysia
- Employees
- NTIC N/A
- CYCC N/A
- Industry
- NTIC Industrial Specialties
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- NTIC Industrials
- CYCC Health Care
- Exchange
- NTIC Nasdaq
- CYCC Nasdaq
- Market Cap
- NTIC 70.0M
- CYCC 61.2M
- IPO Year
- NTIC N/A
- CYCC N/A
- Fundamental
- Price
- NTIC $7.39
- CYCC $0.37
- Analyst Decision
- NTIC Buy
- CYCC
- Analyst Count
- NTIC 1
- CYCC 0
- Target Price
- NTIC $20.00
- CYCC N/A
- AVG Volume (30 Days)
- NTIC 26.6K
- CYCC 823.5K
- Earning Date
- NTIC 07-10-2025
- CYCC 05-15-2025
- Dividend Yield
- NTIC 3.03%
- CYCC 648.65%
- EPS Growth
- NTIC N/A
- CYCC N/A
- EPS
- NTIC 0.38
- CYCC N/A
- Revenue
- NTIC $84,445,763.00
- CYCC $14,000.00
- Revenue This Year
- NTIC $2.05
- CYCC $137.21
- Revenue Next Year
- NTIC $4.70
- CYCC N/A
- P/E Ratio
- NTIC $19.00
- CYCC N/A
- Revenue Growth
- NTIC 2.11
- CYCC N/A
- 52 Week Low
- NTIC $6.75
- CYCC $0.35
- 52 Week High
- NTIC $18.79
- CYCC $39.84
- Technical
- Relative Strength Index (RSI)
- NTIC 46.91
- CYCC 22.52
- Support Level
- NTIC $7.18
- CYCC $1.36
- Resistance Level
- NTIC $7.31
- CYCC $1.73
- Average True Range (ATR)
- NTIC 0.14
- CYCC 0.31
- MACD
- NTIC 0.07
- CYCC -0.07
- Stochastic Oscillator
- NTIC 84.00
- CYCC 0.96
About NTIC Northern Technologies International Corporation
Northern Technologies International Corp, or NTIC is a United States-based firm that develops and markets environmentally beneficial products and services world-wide either directly or through a network of joint ventures, distributors, and agents. It operates through two segments which include ZERUST products and services and Nature-Tec products. Its main business is providing corrosion prevention solutions that are marketed under the ZERUST brand. The company also sells a portfolio of bio-based and biodegradable (compostable) polymer resin compounds and finished products marketed under the Nature-Tec brand. The ZERUST brand generates a vast majority of the revenue for the company.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.